Indian Journal of Pharmaceutical Sciences
Users online: 132
Scientific Publication of the Indian Pharmaceutical Association
Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
The Journal Search Current Issue Archives Instructions Online submission Login  
RESEARCH PAPER
Year : 2010  |  Volume : 72  |  Issue : 4  |  Page : 414-420

Interchangeability of two 500 mg amoxicillin capsules with one 1000 mg amoxicillin tablet after a single oral administration


1 College of Pharmacy, An-Najah National University, Nablus, Palestine,
2 Department of Pharmaceutical Sciences, Ferrara University, Ferrara,
3 Pharmacare Chemical and Cosmetics, Ramallah, Palestine,

Correspondence Address:
R Cortesi
Department of Pharmaceutical Sciences, Ferrara University, Ferrara

Login to access the Email id


DOI: 10.4103/0250-474X.73904

PMID: 21218049

Get Permissions

The aim of the study was to evaluate if two capsules (Amoxil® capsules, 500 mg/capsule) and one tablet (Amoxicare® tablets, 1000 mg/tablet) of amoxicillin have similar bioequivalence parameters. For this purpose a randomized, two-way, crossover, bioequivalence study was performed in 24 healthy, male volunteers, divided into two groups of 12 subjects each. One group was treated with the reference standard (Amoxil® ) and the other one with the generic tablet Amoxicare® , with a crossover after a wash-out period of 7 days. Blood samples were collected at fixed time intervals and amoxicillin was determined by a validated HPLC method. The pharmacokinetic parameters AUC 0-8 , AUC 0-͵, C max , T max , K e and T 1/2 were determined for both formulations and statistically compared to evaluate the bioequivalence between the two brands of amoxicillin, using the statistical model recommended by the FDA. C max and AUC 0-͵ were statistically analyzed using analysis of variance (ANOVA); no statistically significant difference was observed between the two formulations. The 90% confidence intervals between the mean values of C max and AUC 0-͵ fall within the FDA specified bioequivalent limits (80-125%) suggesting that the two products are bioequivalent and the two formulations are interchangeable. Based on these findings it was concluded that the practice of interchangeability between the above formulations to achieve better patient compliance could be followed without compromising the extent of amoxicillin absorption.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3021    
    Printed140    
    Emailed7    
    PDF Downloaded712    
    Comments [Add]    

Recommend this journal